Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2005 Nov;66(6):501–510. doi: 10.1016/j.curtheres.2005.12.006

Tolerability and feasibility of eptifibatide in acute coronary syndrome in patients at high risk for cardiovascular disease: A retrospective analysis*

Zaher S Azzam 1,2,***, Elias Sa'ad 2, Amal Jabareen 1,2, Oron Eilam 1,2, Petru Bartha 1,2, Salim Hadad 3, Norberto Krivoy 1,2
PMCID: PMC3965992  PMID: 24678072

Abstract

Background:

Despite the beneficial effects of glycoprotein (GP) IIb/IIIa antagonists in patients with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), GP IIb/IIIa antagonists are rarely administered in general internal medicine wards in Israel, where most patients with UA/ NSTEMI are admitted, due to lack of adequate monitoring and safety concerns.

Objective:

The aims of this study were to compare the prevalence of bleeding complications in patients with UA/NSTEMI receiving combination treatment with eptifibatide (a GP IIb/IIIa antagonist), the low-molecular-weight heparin enoxaparin, and acetylsalicylic acid (ASA) versus that in patients receiving enoxaparin and ASA in internal medicine wards in Israel, and to identify risk factors for bleeding complications.

Methods:

This retrospective analysis included information from the database at Rambam Medical Center, Haifa, Israel. The database provided information from 4 of the 5 wards (the ward from which data were unavailable did not routinely use eptifibatide). Data were included from patients aged ≥l.8 years who were admitted to the center with a diagnosis of UA/NSTEMI, were at high risk for death and/or nonfatal ischemic events based on American College of Cardiology/American Heart Association guidelines, were to undergo coronary intervention, and who had a Thrombosis in Myocardial Infarction risk score ≥3 (moderate to high risk). Patients in the eptifibatide group received eptifibatide IV (180-μg/kg bolus followed by a continuous infusion of 2 μg/kg · min up to 72 hours), enoxaparin SC (2 mg/kg · d), and ASA (100 mg/d). Patients in the control group received enoxaparin SC (2 mg/kg - d up to 96 hours) and ASA (100 mg/d). The prevalence of bleeding events was assessed using data up to 24 hours after the end of study drug administration. Major bleeding was defined as life-threatening bleeding at any site, intracranial hemorrhage, or bleeding accompanied by a decrease in plasma hemoglobin concentration of 5 g/dL or more. Otherwise, bleeding was considered minor. The risk for bleeding events was assessed using multivariate regression analysis.

Results:

Data from 105 patients (64 men, 41 women) were included in the analysis. In the eptifibatide and control groups, the mean (SD) ages were 68.7 (11.1) and 74.8 (11.0) years, respectively. These characteristics were statistically similar between the 2 groups. The rates of major bleeding were similar between the eptifibatide and control groups (2 [3.8%] vs 0 patients). The rate of minor bleeding was significantly higher in the eptifibatide group compared with that in controls (11 [21.2%] vs 4 [7.5%] patients; P = 0.03). The incidence of thrombocytopenia was statistically similar between the eptifibatide and control groups (0 vs 2 [3.8%] patients). The risk for bleeding was found to be associated with eptifibatide use (odds ratio, 4.8; 95% CI, 1.29–17.80), whereas an association with treatment was not found in the control group.

Conclusion:

The results of this retrospective analysis suggest that the risk for bleeding complications is higher with combination treatment with eptifibatide, enoxaparin, and ASA compared with that with enoxaparin and ASA in high-risk patients with UA/NSTEMI admitted to internal medicine wards in Israel.

Key words: GP IIb/IIIa antagonists, eptifibatide, unstable angina and non-ST-segment elevation myocardial infarction, bleeding, Thrombosis in Myocardial Infarction risk score, aspirin, low-molecular-weight heparin, enoxaparin, anti-coagulation, combination

Full Text

The Full Text of this article is available as a PDF (572.6 KB).

Footnotes

*

This study was presented in part in poster form at the 20th International Conference on Pharmaco-epidemiology and Therapeutic Risk Management, August 22–25, 2004, Bordeaux, France.

References

  • 1.Yeghiazarians Y., Braunstein J.B., Askari A., Stone P.H. Unstable angina pectoris. N Engl J Med. 2000;342:101–114. doi: 10.1056/NEJM200001133420207. [DOI] [PubMed] [Google Scholar]
  • 2.Simoons M.L., GUSTO IV-ACS Investigators Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915–1924. doi: 10.1016/s0140-6736(00)05060-1. [DOI] [PubMed] [Google Scholar]
  • 3.Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Qwave myocardial infarction. N Engl J Med. 1998;338:1488–1497. doi: 10.1056/NEJM199805213382102. [published correction appears in N Engl J Med. 1998;339: 415] [DOI] [PubMed] [Google Scholar]
  • 4.Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498–1505. doi: 10.1056/NEJM199805213382103. [DOI] [PubMed] [Google Scholar]
  • 5.The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor suppression using integrilin therapy. N Engl J Med. 1998;339:436–443. [Google Scholar]
  • 6.Boersma E., Harrington R.A., Moliterno D.J. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189–198. doi: 10.1016/S0140-6736(02)07442-1. [published correction appears in Lancet. 2002;359:2120] [DOI] [PubMed] [Google Scholar]
  • 7.Boersma E., Akkerhuis K.M., Theroux P. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045–2048. doi: 10.1161/01.cir.100.20.2045. [DOI] [PubMed] [Google Scholar]
  • 8.Scarborough R.M. Development of eptifibatide. Am Heart J. 1999;138:1093–1104. doi: 10.1016/s0002-8703(99)70075-x. [DOI] [PubMed] [Google Scholar]
  • 9.Ferguson J.J., Antman E.M., Bates E.R., NICE-3 Investigators Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: Final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003;146:628–634. doi: 10.1016/S0002-8703(03)00165-0. [DOI] [PubMed] [Google Scholar]
  • 10.Ferguson J. Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes. J Invasive Cardiol. 2004;16:136–144. [PubMed] [Google Scholar]
  • 11.Kovar D., Canto J.G., Rogers W.J. Safety and effectiveness of combined low molecular weight heparin and glycoprotein IIb/IIIa inhibitors. Am J Cardiol. 2002;90:911–915. doi: 10.1016/s0002-9149(02)02652-8. [DOI] [PubMed] [Google Scholar]
  • 12.Boersma E., Pieper K.S., Steyerberg E.W., PURSUIT Investigators Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. Circulation. 2000;101:2557–2567. doi: 10.1161/01.cir.101.22.2557. [DOI] [PubMed] [Google Scholar]
  • 13.Antman E.M., Cohen M., Bernink P.J. The TIMI risk score for unstable angina/nonST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284:835–842. doi: 10.1001/jama.284.7.835. [DOI] [PubMed] [Google Scholar]
  • 14.Braunwald E., Antman E.M., Beasley J.W., American College of Cardiology, American Heart Association, Committee on the Management of Patients with Unstable Angina ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarctionsummary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina) J Am Coll Cardiol. 2002;40:1366–1374. doi: 10.1016/s0735-1097(02)02336-7. [DOI] [PubMed] [Google Scholar]
  • 15.Rao A.K., Pratt C., Berke A. Thrombolysis in Myocardial Infarction (TIMI) Trialphase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11. doi: 10.1016/0735-1097(88)90158-1. [DOI] [PubMed] [Google Scholar]
  • 16.Hirsch R.P., Riegelman R.K., editors. Nominal dependent variables. 1st ed. Blackwell Scientific; Boston, Mass: 1992. pp. 167–201. (Statistical First Aid: Interpretation of Health Research Data). [Google Scholar]
  • 17.Bhatt D.L., Lee B.I., Casterella P.J., Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary interven tion: Results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol. 2003;41:20–25. doi: 10.1016/s0735-1097(02)02631-1. [DOI] [PubMed] [Google Scholar]
  • 18.Cohen M. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: An update. Drugs. 2002;62:1755–1770. doi: 10.2165/00003495-200262120-00005. [DOI] [PubMed] [Google Scholar]
  • 19.Goodman S.G., Fitchett D., Armstrong P.W., Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003;107:238–244. doi: 10.1161/01.cir.0000050144.67910.13. [DOI] [PubMed] [Google Scholar]
  • 20.Budaj A., Brieger D., Steg P.G., GRACE Investigators Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events (GRACE) Am Heart J. 2003;146:999–1006. doi: 10.1016/S0002-8703(03)00509-X. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES